Intrinsic Value of S&P & Nasdaq Contact Us

Evolus, Inc. EOLS NASDAQ

NASDAQ Global Market • Healthcare • Drug Manufacturers - Specialty & Generic • US • USD

SharesGrow Score
57/100
3/7 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow
Analyst Price Target
$15.00
+237.8%

Evolus, Inc. (EOLS) — Analyst outlook / Analyst consensus target is. Based on 13 analyst ratings, the consensus is bullish — 11 Buy, 2 Hold.

The consensus price target is $15.00 (low: $13.00, high: $17.00), representing an upside of 237.8% from the current price $4.44.

Analysts estimate Earnings Per Share (EPS) of $-0.27 and revenue of $0.27B for the next fiscal year.

Earnings Per Share (EPS) track record: 2024: actual $-0.81 vs est $-0.27 (missed -200%). 2025: actual $-0.80 vs est $-0.45 (missed -77.5%). Analyst accuracy: 45%.

EOLS Stock — 12-Month Price Forecast

$15.00
▲ +237.84% Upside
Average Price Target
Based on 13 Wall Street analysts offering 12-month price targets for Evolus, Inc., the average price target is $15.00, with a high forecast of $17.00, and a low forecast of $13.00.
The average price target represents a +237.84% change from the last price of $4.44.
Highest Price Target
$17.00
Average Price Target
$15.00
Lowest Price Target
$13.00

EOLS Analyst Ratings

Buy
13
Ratings
11 Buy
2 Hold
Based on 13 analysts giving stock ratings to Evolus, Inc. in the past 3 months
Rating breakdown
Buy
11 85%
Hold
2 15%
85%
Buy
11 analysts
15%
Hold
2 analysts
0%
Sell
0 analysts

EPS Estimates — EOLS

45%
Analyst Accuracy
Inaccurate
2 years compared
Actual vs Estimate
2024 Actual –$0.81 vs Est –$0.27 ▼ 66.7% off
2025 Actual –$0.80 vs Est –$0.45 ▼ 43.7% off
Profitability Outlook
Company has been making losses in all recent fiscal years. EPS is improving but still negative. Analysts expect losses to continue near-term.

Revenue Estimates — EOLS

100%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024 Actual $0.266B vs Est $0.266B ▼ 0.0% off
2025 Actual $0.297B vs Est $0.296B ▲ 0.2% off
Revenue Trend
Moderate revenue growth trend. Analysts forecast revenue contraction ahead.
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
Send us a message